Diabetes mellitus and Parkinson's disease: dangerous liaisons between insulin and dopamine
Angela De Iuliis1
Ennio Montinaro2
Giuseppe Fatati3
Mario Plebani4
Carlo Colosimo2
1.Department of Medicine-DiMED,University of Padova,Italy2.Department of Neurology,Santa Maria University Hospital,Terni,Italy3.Italian Obesity Network,Terni,Italy4.Department of Medicine-DiMED,University of Padova,Italy;Department of Medicine-DiMED,University of Padova,Padova,Italy,Department of Laboratory Medicine-Hospital of Padova,Padova,Italy
摘要：The relationship between diabetes mellitus and Parkinson's disease has been described in several epidemiological studies over the 1960s to date. Molecular studies have shown the possible functional link between insulin and dopamine, as there is strong evidence demonstrating the action of dopamine in pancreatic islets, as well as the insulin effects on feeding and cognition through central nervous system mechanism, largely independent of glucose utilization. Therapies used for the treatment of type 2 diabetes mellitus appear to be promising candidates for symptomatic and/or disease-modifying action in neurodegenerative diseases including Parkinson's disease, while an old dopamine agonist, bromocriptine, has been repositioned for the type 2 diabetes mellitus treatment. This review will aim at reappraising the different studies that have highlighted the dangerous liaisons between diabetes mellitus and Parkinson's disease.
机标关键词：
论文发表日期：2022-03-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：11( 523-533 )
英文信息